K

    Kala Pharmaceuticals Inc (KALA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.68
    -0.01 (-0.88%)

    Market Cap: $13.35M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(17/35)
    Avg Surprise
    -72.47%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 6
    		$-21.32N/AN/ABeat+57.9%
    Mar 26
    Reported Apr 15
    		$-0.14$-0.17+19.71%Beat+88.9%
    Sep 25
    Reported Nov 19
    		$-53.50$-50.50-5.94%Miss+44.6%
    Jun 25
    Reported Aug 8
    		$-65.94$-102.00+35.35%Beat+46.1%
    Mar 25
    Reported May 14
    		$-50.66N/A+60.11%Beat-1109.1%
    Dec 24
    Reported Mar 31
    		$-1.23N/A+50.14%Beat+98.4%
    Sep 24
    Reported Nov 12
    		$-96.50$-135.50+28.78%Beat+35.7%
    Jun 24
    Reported Aug 6
    		$-122.27$-229.00+46.61%Beat+29.8%
    Mar 24
    Reported May 14
    		$-4.19$-2.89-44.98%Miss+40.1%
    Dec 23
    Reported Mar 29
    		$-79.07N/A+60.47%Beat+75.5%
    Sep 23
    Reported Nov 13
    		$-150.12$23.00-752.70%Miss+66.6%
    Jun 23
    Reported Aug 4
    		$-174.05$-214.50+18.86%Beat+80.1%
    Mar 23
    Reported May 9
    		$-6.99$-4.52-54.65%Miss+99.3%
    Dec 22
    Reported Mar 3
    		$-323.17$-382.50+15.51%Beat-850.5%
    Sep 22
    Reported Nov 8
    		$-449.33N/A-130.99%Miss+51.4%
    Jun 22
    Reported Aug 11
    		$-872.50$-900.00+3.06%Beat+12.8%
    Mar 22
    Reported May 16
    		$-1001.00$-720.10-39.01%Miss+2.3%
    Dec 21
    Reported Mar 29
    		$-34.00$-20.33-67.24%Miss-23.6%
    Sep 21
    Reported Nov 15
    		$-925.00$-978.61+5.48%Beat+26.0%
    Jun 21
    Reported Aug 5
    		$-1000.00$-975.30-2.53%Miss+4.8%
    Mar 21
    Reported May 5
    		$-1025.00$-1108.33+7.52%Beat+24.1%
    Dec 20
    Reported Feb 25
    		$-27.50$-22.92-19.98%Miss+98.3%
    Sep 20
    Reported Nov 5
    		$-1250.00$-1134.23-10.21%Miss+26.5%
    Jun 20
    Reported Aug 6
    		$-1050.00$-942.49-11.41%Miss+40.0%
    Mar 20
    Reported May 7
    		$-1350.00$-1500.00+10.00%Beat+28.0%
    Dec 19
    Reported Feb 12
    		$-1575.00$-1556.46-1.19%Miss-4044.7%
    Sep 19
    Reported Nov 7
    		$-1700.00$-1619.39-4.98%Miss-7.9%
    Jun 19
    Reported Aug 6
    		$-1750.00$-1853.70+5.59%Beat-16.7%
    Mar 19
    Reported May 9
    		$-1875.00$-2013.42+6.87%Beat-63.0%
    Dec 18
    Reported Mar 11
    		$-38.00$-26.10-45.59%Miss-65.2%
    Sep 18
    Reported Nov 8
    		$-1575.00$-1600.00+1.56%Beat-12.5%
    Jun 18
    Reported Aug 9
    		$-1500.00$-1233.33-21.62%Miss-222.6%
    Mar 18
    Reported May 10
    		$-1150.00$-1157.39+0.64%Beat-199900.0%
    Dec 17
    Reported Mar 26
    		$-23.00$-18.50-24.32%Miss-
    Sep 17
    Reported Nov 7
    		$-1400.00$-1062.50-31.76%Miss-
    Jun 17
    Reported Aug 31
    		$-465.00$-26.67-1643.53%Miss-
    Mar 17
    Reported May 31
    		$-0.57$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDA-0.16x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-345.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio6.88xQuick Ratio6.88x
    Trading Statistics
    Beta-2.28Avg Volume185.90K
    52-Week High$1030.0052-Week Low$0.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.81
    SMA 20$0.81
    SMA 50$1.15
    SMA 200$14.30
    EMA 10$0.78
    EMA 20$0.83
    EMA 50$1.58
    EMA 200$48.41

    MACD

    Line: -0.10Signal: -0.12Hist: 0.02

    ADX

    ADX: 15.9+DI: 21.6-DI: 10.8

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down96.0
    PSAR$0.59

    Bollinger Bands

    Upper Band$0.98
    Lower Band$0.65
    %B Position3973%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    31.2

    Momentum Oscillators

    Stoch %K23.9
    Stoch %D29.5
    Williams %R-80.8
    ROC (10d)-24.9%
    Momentum-0.23
    CCI (20d)-137.5
    MFI (14d)15.4

    Volatility Measures

    ATR (14d)$0.16(22.8%)
    StdDev (20d)0.08
    Hist Vol87.9%(High)

    Volume Flow

    VWAP$0.70
    OBV482.0M
    AD Line411.4B
    CMF (20d)-0.500

    Volume Metrics

    Avg Vol (20d)192.3K
    Vol Ratio1.2x
    VWMA (20d)$0.73

    Pivot Points

    R3$1.50
    R2$1.30
    R1$0.99
    Pivot Point$0.79
    S1$0.49
    S2$0.28
    S3$-0.02

    Advanced Oscillators

    TSI-27.30
    Ultimate Osc26.0
    KST-52.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$254,000$0$0$0$70,000$0
    Cost of Revenue$0$0N/A$0$0$0$69,000$0$0$0$70,000$0
    Gross Profit$0$0N/A$0$0$0$-69,000$0$0$0$-70,000$0
    Operating Expenses$1.72M$1.80M$10.22M$7.24M$11.03M$10.65M$9.46M$9.99M$9.61M$11.93M$9.62M$8.76M
    R&D$59,000$61,000$366,000$6.13M$6.23M$6.05M$5.26M$5.17M$5.32M$6.35M$4.72M$5.55M
    SG&A$1.66M$1.74M$9.86M$4.53M$4.64M$4.59M$4.20M$4.40M$4.32M$5.42M$4.62M$4.95M
    Operating Income$-1,721,000$-1,802,000$-10,225,000$-7,239,000$-11,028,000$-10,669,000$-9,459,000$-9,988,000$-9,605,000$-11,931,000$-9,619,000$-8,762,000
    Interest Income$140,000$74,000$0$270,000$407,000$463,000$478,000$570,000$504,000$504,000$610,000$708,000
    Interest Expense$0$0$-5,652,000$963,000$1.08M$1.09M$1.39M$1.48M$1.46M$1.46M$1.47M$1.46M
    Income Before Tax$-1,581,000$-1,621,000$686,000$-7,564,000$-11,155,000$-11,297,000$-8,175,000$-8,950,000$-9,579,000$-11,807,000$-8,627,000$-8,704,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,581,000$-1,621,000$686,000$-7,564,000$-11,155,000$-11,297,000$-8,175,000$-8,950,000$-9,579,000$-11,807,000$-8,627,000$-8,704,000
    EBITDA$-1,721,000$-1,695,000$-6,054,000$-6,627,000$-10,241,000$-10,415,000$-6,893,000$-7,657,000$-8,249,000$-10,478,000$-7,387,000$-7,565,000
    EBIT$-1,721,000$-1,695,000$-4,966,000$-6,871,000$-10,481,000$-10,669,000$-7,261,000$-8,042,000$-8,625,000$-10,856,000$-7,769,000$-7,953,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KALA

    News

    Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

    Kala Bio and Virotek have signed a letter of intent for an exclusive U.S. distribution partnership for Virotek's ophthalmology genetic testing and screening program. This collaboration will allow Kala Bio to market and distribute the program to eye care practices, telehealth platforms, and other channels, leveraging its existing relationships in the eye care community. The partnership aims to provide Kala Bio with near-term revenue generation in a therapeutic area it knows well, with potential expansion into other clinical verticals.

    Yahoo! Finance Canada•9/1/26•
    Bullish

    KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable

    KALA's net loss significantly narrowed year-over-year as the company shifted its focus from biologics R&D to an AI platform for biotech clients. This improvement was supported by reduced operating expenses, new financing, and a $7M note receivable, with operations funded through Q3 2027. The information is based on an SEC 10-Q Quarterly Report.

    TradingView•8/19/26•
    Bullish

    KALA BIO (KALA) pivots to biotech AI with $229K on hand

    KALA BIO (KALA) is transitioning its business from ophthalmology biologics to an AI infrastructure platform for biotechnology clients, following the discontinuation of its KPI-012 MSC-S program. The company reported a significantly reduced net loss of $3.2 million for the first half of 2026, down from $20.1 million in the prior year, largely due to decreased R&D and general administrative expenses. KALA BIO has licensed Younet's Researgency biomedical AI platform and secured a $55 million option to acquire Younet, while holding $229 thousand in cash and a $7.0 million short-term loan receivable from Minglemint Solutions.

    Stock Titan•8/19/26•
    Somewhat-Bearish

    KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary

    KALA BIO, Inc. reported a reduced net loss of $(1.58M) and an EPS of $(21.32) for Q2 2026, significantly improving from the prior year. This financial improvement is attributed to a strategic pivot towards an on-premises Researgency AI platform, away from biologics R&D, and substantial operational cost reductions. The company is maintaining a dual-track approach, exploring licensing options for MSC-S biologics while developing its AI platform.

    TradingView•8/19/26•
    Somewhat-Bullish

    KALA BIO: Q2 Earnings Snapshot

    KALA BIO, Inc. reported a loss of $1.6 million in its second quarter, amounting to $21.32 per share. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research. The report highlights the company's Q2 performance with a specific focus on its net loss.

    KTVB•8/19/26•
    Bearish

    Frequently Asked Questions About KALA

    Does KALA pay dividends?
    Kala Pharmaceuticals Inc (KALA) does not currently pay a regular dividend.
    What is KALA's market cap?
    Kala Pharmaceuticals Inc (KALA) has a market capitalization of $13.35M with a current stock price of $0.68.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In